Premonitory symptoms in migraine from China: A multi-clinic study of 4821 patients.
- Published in:
- Cephalalgia, 2021, v. 41, n. 9, p. 991, doi. 10.1177/0333102421997850
- By:
- Publication type:
- Article
Works matching IS 03331024 AND DT 2021 AND VI 41 AND IP 9
Results: 9
1
2
Trans-nasal high-flow dehumidified air in acute migraine headaches: A randomized controlled trial.
- Published in:
- Cephalalgia, 2021, v. 41, n. 9, p. 968, doi. 10.1177/0333102421997766
- By:
- Publication type:
- Article
3
Two hundred and forty-eight cases of visual snow: A review of potential inciting events and contributing comorbidities.
- Published in:
- Cephalalgia, 2021, v. 41, n. 9, p. 1015, doi. 10.1177/0333102421996355
- By:
- Publication type:
- Article
4
Effect of single dose Erenumab on cortical responses evoked by cutaneous a-delta fibers: A pilot study in migraine patients.
- Published in:
- Cephalalgia, 2021, v. 41, n. 9, p. 1004, doi. 10.1177/0333102421996345
- By:
- Publication type:
- Article
5
Board Walk - August 2021.
- Published in:
- 2021
- By:
- Publication type:
- Editorial
6
CORRIGENDUM to 'Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN'.
- Published in:
- 2021
- Publication type:
- Correction Notice
7
Time lost due to an attack – a novel patient-reported outcome measure for acute migraine treatments.
- Published in:
- Cephalalgia, 2021, v. 41, n. 9, p. 1027, doi. 10.1177/03331024211006048
- By:
- Publication type:
- Article
8
The first prevalence study of primary headaches in adults in a post-conflict area of Serbia.
- Published in:
- Cephalalgia, 2021, v. 41, n. 9, p. 959, doi. 10.1177/03331024211006043
- By:
- Publication type:
- Article
9
Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II.
- Published in:
- Cephalalgia, 2021, v. 41, n. 9, p. 979, doi. 10.1177/03331024211000311
- By:
- Publication type:
- Article